BRPI0409424A - composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença - Google Patents

composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença

Info

Publication number
BRPI0409424A
BRPI0409424A BRPI0409424-7A BRPI0409424A BRPI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A
Authority
BR
Brazil
Prior art keywords
treating
patient suffering
pharmaceutical composition
parenteral administration
polypeptide
Prior art date
Application number
BRPI0409424-7A
Other languages
English (en)
Inventor
Moshe Baru
Lea Carmel-Goren
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Publication of BRPI0409424A publication Critical patent/BRPI0409424A/pt
Publication of BRPI0409424B1 publication Critical patent/BRPI0409424B1/pt
Publication of BRPI0409424B8 publication Critical patent/BRPI0409424B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA ADMIMSTRAçãO PARENTERAL, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE HEMOFILIA, USO DE UMA PARTìCULA COLOIDAL, E, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE UMA DOENçA". Uma composição farmacêutica para administração parenteral compreendendo uma quantidade terapeuticamente efetiva de uma proteína ou um polipeptídeo e partículas coloidais. As partículas compreendem aproximadamente 1-20 porcento em mol de um lipídeo anfipático derivado com um polímero hidrofílico biocompatível. A proteína ou o polipeptídeo é selecionada(o) do grupo consistindo de: (a) proteínas ou polipeptídeos capazes de se ligar externamente nas citadas partículas coloidais; (b) proteínas ou polipeptídeos capazes de se ligar em polímeros de famílias de poli(alquiléter), poli(ácido lático) e poli(ácido glicólico); e (c) proteínas ou polipeptídeos que incluem uma seqüência de consenso de S/T-X/I/V-I/V/Q/SS/T-X-X-X-E, na qual X pode ser qualquer aminoácido, e S, T, L, I, E, e Q possuem os significados padrão. A proteína ou o polipeptídeo não é Fator VIII (FVIII) e não está encapsulada(o) nas partículas coloidais.
BRPI0409424A 2003-04-15 2004-04-15 composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo BRPI0409424B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46270103P 2003-04-15 2003-04-15
US60/462,701 2003-04-15
PCT/IL2004/000327 WO2004091723A1 (en) 2003-04-15 2004-04-15 Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles

Publications (3)

Publication Number Publication Date
BRPI0409424A true BRPI0409424A (pt) 2006-04-25
BRPI0409424B1 BRPI0409424B1 (pt) 2018-05-02
BRPI0409424B8 BRPI0409424B8 (pt) 2021-05-25

Family

ID=33299976

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409424A BRPI0409424B8 (pt) 2003-04-15 2004-04-15 composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo

Country Status (15)

Country Link
US (1) US20070167359A1 (pt)
EP (1) EP1633440B1 (pt)
JP (1) JP2006523683A (pt)
CN (1) CN1774281B (pt)
AT (1) ATE395101T1 (pt)
AU (1) AU2004229253B2 (pt)
BR (1) BRPI0409424B8 (pt)
CA (1) CA2522179C (pt)
DE (1) DE602004013769D1 (pt)
DK (1) DK1633440T3 (pt)
ES (1) ES2307009T3 (pt)
MX (1) MXPA05010926A (pt)
PL (1) PL1633440T3 (pt)
PT (1) PT1633440E (pt)
WO (1) WO2004091723A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (en) * 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH0482839A (ja) * 1990-07-20 1992-03-16 Green Cross Corp:The 蛋白質類・脂質小体複合体
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JP2001508783A (ja) * 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
WO1999055306A1 (en) * 1998-04-27 1999-11-04 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
DE60026030T2 (de) * 1999-07-14 2006-08-10 Alza Corp., Mountain View Neutrales lipopolymer und liposomale zusammensetzungen daraus
CA2400374A1 (en) * 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
WO2002086117A1 (en) * 2001-04-20 2002-10-31 The University Of Vermont Compositions and methods to control bleeding
JP2005521645A (ja) * 2001-12-04 2005-07-21 ベン グリオン ユニバーシティ オブ ザ ネジェブ リサーチ アンド ディベラップメント オーソリティ 器官特異的薬物ターゲティング用両親媒性化合物及び小胞／リポソーム

Also Published As

Publication number Publication date
US20070167359A1 (en) 2007-07-19
MXPA05010926A (es) 2005-11-25
BRPI0409424B1 (pt) 2018-05-02
CN1774281A (zh) 2006-05-17
PT1633440E (pt) 2008-08-25
ATE395101T1 (de) 2008-05-15
EP1633440A1 (en) 2006-03-15
CA2522179C (en) 2012-02-14
AU2004229253B2 (en) 2009-11-05
PL1633440T3 (pl) 2008-12-31
DK1633440T3 (da) 2008-09-08
JP2006523683A (ja) 2006-10-19
WO2004091723A1 (en) 2004-10-28
DE602004013769D1 (de) 2008-06-26
BRPI0409424B8 (pt) 2021-05-25
AU2004229253A1 (en) 2004-10-28
CN1774281B (zh) 2010-10-13
ES2307009T3 (es) 2008-11-16
EP1633440B1 (en) 2008-05-14
CA2522179A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
CN105189532B (zh) 用于伤口愈合、皮肤护理和化妆品应用的自组装超短肽水凝胶
EP1120439B1 (en) Injectable ceramic compositions and methods for their preparation and use
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
JP2006131648A (ja) コラーゲンベースの注入可能な薬剤送達製剤およびその使用
JPH11512740A (ja) 増殖因子を含むゲル組成物
US8029769B2 (en) Protein formulation
Takaoka et al. Bone regeneration by lactoferrin released from a gelatin hydrogel
MXPA05002991A (es) Analogos de ghrh.
JP2001521414A (ja) 移植可能なパテ状材料
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DE69819488D1 (de) Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
JP2022552832A (ja) タンパク質の送達のための組成物
Silva et al. Inflammatory response to dextrin-based hydrogel associated with human mesenchymal stem cells, urinary bladder matrix and Bonelike® granules in rat subcutaneous implants
US20050244393A1 (en) Sealant or tissue generating product
BRPI0409424A (pt) composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença
CA2589095C (en) Protein formulation for administering an active enamel substance
BR9202374A (pt) Composicao implantavel para a administracao parenteral de uma quantidade essencialmente uniforme e continua de uma proteina,um peptideo ou polipeptideo biologicamente ativos,processo de elevar e manter elevados niveis no sangue de uma proteina,peptideo ou polipeptideo biologicamente ativos e processo para a preparacao da composicao implantavel
JPH06157339A (ja) 骨形成組成物及びその使用方法
US20050112087A1 (en) Pharmaceutical formulations for sustained drug delivery
EP1862170A1 (en) Protein formulation
US20230010110A1 (en) Histatin-1 formulation for the treatment, repair or regeneration of bone tissue in a subject
AU2011203284B2 (en) Protein Formulation
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
JPH10167987A (ja) 徐放性製剤

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED (MT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF